CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum

NEUROBIOLOGY OF AGING

卷:74

Article

Rauchmann, Boris-Stephan^1,2  Schneider-Axmann, Thomas²  Alexopoulos, Panagiotis^3,4  Perneczky, Robert^2,5,6,7 

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Psychiat & Psychotherapy, Munich, Germany

[3] Univ Patras, Univ Hosp Rion, Dept Psychiat, Patras, Greece

[4] Tech Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany

[5] German Ctr Neurodegenerat Dis DZNE Munich, Munich, Germany

[6] Munich Cluster Syst Neurol SyNergy, Munich, Germany

[7] Imperial Coll London, Sch Publ Hlth, Ageing Epidemiol Res Unit, London, England

关键词: Alzheimer's disease;    Dementia;    Mild cognitive impairment;    Biomarker;    Neuroinflammation;    Neurodegeneration;    Imaging;    Prediction;   

DOI  :  10.1016/j.neurobiolaging.2018.10.022

来源: Elsevier

【 摘 要 】

TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) when using clinical criteria to classify Alzheimer's disease (AD). The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort. Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National Institute on Aging-Alzheimer's Association research framework guidelines, which group biomarkers into those of amyloid-beta deposition, tau pathology, and neurodegeneration. CSF sTREM2 concentrations were associated with markers of neurodegeneration and fibrillar tau pathology, but not amyloidosis; sTREM2 concentrations were increased in total tau-positive versus -negative individuals; sTREM2 was not related to cognitive and other biomarker changes over time; and sTREM2 concentrations increased over time in total tau-positive versus -negative individuals with AD pathophysiology. The present study provides evidence in support of sTREM2 in CSF as a marker of neuroinflammation across the spectrum of early clinical AD. sTREM2 is linked to neuronal injury and may therefore offer complementary information relevant for diagnostic purposes and novel treatment approaches targeting the immune system in AD. (C) 2018 Elsevier Inc. All rights reserved.

【 授权许可】

Free